Figure 6
Rosiglitazone concomitantly increases mitochondrial contents and UCP-1 expression in the multilocular adipocytes of the adult adipose tissues. The indicated adipose tissues were harvested from C57BL/6J mice that had been treated with nothing (Control) or rosiglitazone (~15 mg/kg/day) for 3 weeks. (A, C, E) Tissues were whole-mounted, co-immunostained for collagen IV and Mitotracker, and stained with BODIPY 493/503 (BD, for lipid droplets) (A); co-immunostained for UCP-1 and Mitotracker, and merged (B); or co-immunostained for UCP-1, collagen IV, and perilipin, and merged (E). White arrowheads in A and white arrows in C point to rosiglitazone-induced multilocular adipocytes that contain substantially increased mitochondrial content and UCP-1 expression. Scale bars, 20 µm. (B, D) Positive signals for Mitotracker or UCP-1 for a given cell number (~1,500; ~300/each region) at 5 regions per adipose tissue in each mouse of Control (n = 3) or rosiglitazone (n = 3) were quantified and presented as %, with the total cells as 100%. Bars represent the mean ± SD. *P < 0.01 versus control.
